These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 30552308)

  • 21. Mechanisms and Characteristics of Sulfonylureas and Glinides.
    Lv W; Wang X; Xu Q; Lu W
    Curr Top Med Chem; 2020; 20(1):37-56. PubMed ID: 31884929
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fasting insulin levels correlate with the frequency of hypoglycemic events in people with type 2 diabetes on treatment with sulfonylureas: A pilot study.
    Kolokas K; Koufakis T; Avramidis I; Gerou S; Chatzidimitriou M; Kazakos K; Kotsa K
    Indian J Pharmacol; 2020; 52(1):44-48. PubMed ID: 32201446
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Hypoglycemic risk of insulinotropic drugs].
    Böhm R; Cascorbi I; Herdegen T
    Med Monatsschr Pharm; 2009 Dec; 32(12):453-8. PubMed ID: 20088347
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk of Hypoglycemia and Concomitant Use of Repaglinide and Clopidogrel: A Population-Based Nested Case-Control Study.
    Wei Y; Lin FJ; Lin SY; Wang CC
    Clin Pharmacol Ther; 2019 Dec; 106(6):1346-1352. PubMed ID: 31216051
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Severe hypoglycemia is associated with antidiabetic oral treatment compared with insulin analogs in nursing home patients with type 2 diabetes and dementia: results from the DIMORA study.
    Abbatecola AM; Bo M; Barbagallo M; Incalzi RA; Pilotto A; Bellelli G; Maggi S; Paolisso G;
    J Am Med Dir Assoc; 2015 Apr; 16(4):349.e7-12. PubMed ID: 25669671
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of age, gender, and body mass index on efficacy and hypoglycaemia outcomes across treat-to-target trials with insulin glargine 100 U/mL added to oral antidiabetes agents in type 2 diabetes.
    Owens DR; Bolli GB; Charbonnel B; Haak T; Landgraf W; Porcellati F; Traylor L; Kautzky-Willer A
    Diabetes Obes Metab; 2017 Nov; 19(11):1546-1554. PubMed ID: 28449412
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas.
    Shorr RI; Ray WA; Daugherty JR; Griffin MR
    Arch Intern Med; 1997 Aug 11-25; 157(15):1681-6. PubMed ID: 9250229
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas.
    Ragia G; Petridis I; Tavridou A; Christakidis D; Manolopoulos VG
    Pharmacogenomics; 2009 Nov; 10(11):1781-7. PubMed ID: 19891554
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hypoglycemia during the Concomitant Use of Repaglinide and Clopidogrel in an Elderly Patient with Type 2 Diabetes and Severe Renal Insufficiency.
    Takayama K; Fujii K; Yamaguchi H; Miyoshi Y; Uehara Y; Nagata S; Obata Y; Kosugi M; Hazama Y; Yasuda T
    Intern Med; 2021; 60(6):905-910. PubMed ID: 33716254
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug-induced hypoglycaemia.
    Prescrire Int; 2009 Apr; 18(100):67. PubMed ID: 19585724
    [No Abstract]   [Full Text] [Related]  

  • 31. Preclinical and clinical studies on safety and tolerability of repaglinide.
    Schatz H
    Exp Clin Endocrinol Diabetes; 1999; 107 Suppl 4():S144-8. PubMed ID: 10522841
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inadvertent sulfonylurea overdosage and hypoglycemia in an elderly woman: failure of serum hypoglycemia screening.
    Earle KE; Rushakoff RJ; Goldfine ID
    Diabetes Technol Ther; 2003; 5(3):449-51. PubMed ID: 12828829
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HYPOGLYCEMIA INDUCED BY ANTIDIABETIC SULFONYLUREAS.
    Confederat L; Constantin S; Lupaşcu F; Pânzariu A; Hăncianu M; Profire L
    Rev Med Chir Soc Med Nat Iasi; 2015; 119(2):579-84. PubMed ID: 26204670
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypoglycemia in hospitalized patients treated with sulfonylureas.
    Deusenberry CM; Coley KC; Korytkowski MT; Donihi AC
    Pharmacotherapy; 2012 Jul; 32(7):613-7. PubMed ID: 22570146
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Severe hypoglycaemia the "tip of the iceberg": an underestimated risk in both type 1 and type 2 diabetic patients.
    Halimi S
    Diabetes Metab; 2015 Apr; 41(2):105-6. PubMed ID: 25824635
    [No Abstract]   [Full Text] [Related]  

  • 36. [Measures to meet the side effects of sulfonylurea (SU) in the treatment of type 2 diabetes].
    Furukawa H; Ishida H
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():357-61. PubMed ID: 12387018
    [No Abstract]   [Full Text] [Related]  

  • 37. Rates of hypoglycemia in users of sulfonylureas.
    van Staa T; Abenhaim L; Monette J
    J Clin Epidemiol; 1997 Jun; 50(6):735-41. PubMed ID: 9250272
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk of severe hypoglycemic events from amiodarone-sulfonylureas interactions: A population-based nested case-control study.
    Lai JH; Wang MT; Wu CC; Huang YL; Lu CH; Liou JT
    Pharmacoepidemiol Drug Saf; 2020 Aug; 29(8):842-853. PubMed ID: 32483856
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of prandial glucose regulation with repaglinide in addressing the problem of hypoglycemia in the treatment of type 2 diabetes.
    Owens D
    J Assoc Physicians India; 2001 Jan; 49 Spec No():54-61. PubMed ID: 11235607
    [No Abstract]   [Full Text] [Related]  

  • 40. ABCC8 polymorphism (Ser1369Ala): influence on severe hypoglycemia due to sulfonylureas.
    Sato R; Watanabe H; Genma R; Takeuchi M; Maekawa M; Nakamura H
    Pharmacogenomics; 2010 Dec; 11(12):1743-50. PubMed ID: 21142918
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.